Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €139.19 EUR
Change Today -0.57 / -0.40%
Volume 3.2M
BAYN On Other Exchanges
Symbol
Exchange
OTC US
Xetra
OTC US
BrsaItaliana
Xetra
Mexico
Continuous
As of 2:34 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

bayer ag-reg (BAYN) Snapshot

Open
€138.94
Previous Close
€139.76
Day High
€139.34
Day Low
€134.20
52 Week High
03/16/15 - €145.85
52 Week Low
04/15/14 - €89.49
Market Cap
115.1B
Average Volume 10 Days
2.4M
EPS TTM
€4.56
Shares Outstanding
826.9M
EX-Date
05/28/15
P/E TM
30.5x
Dividend
€2.25
Dividend Yield
1.51%
Current Stock Chart for BAYER AG-REG (BAYN)

bayer ag-reg (BAYN) Related Bloomberg News

View More Bloomberg News

bayer ag-reg (BAYN) Details

Bayer Aktiengesellschaft develops, produces, and markets health care and agricultural products, and high-tech polymer materials worldwide. The company operates through HealthCare, CropScience, and MaterialScience segments. The HealthCare segment offers prescription pharmaceuticals, such as anticoagulants; medicines to treat hemophilia, multiple sclerosis, cancer, eye diseases, pulmonary hypertension, high blood pressure, and infectious diseases; and contraceptives, as well as provides consumer health products, including over-the-counter medications, dermatology products, nutritional supplements, veterinary medicines, and animal grooming products. This segment also provides medical care products, including blood glucose monitoring devices, such as single-strip and multi-strip systems; USB meters that feature integrated diabetes management software and direct plug-in to computers; and contrast agent injection systems for diagnostic and therapeutic medical procedures in X-ray, computed tomography, and magnetic resonance imaging. The CropScience segment offers products in the areas of seeds and plant traits, and crop protection; and products for use in gardens and non-agricultural pest control, as well as green industry. The MaterialScience segment provides high-tech polymer materials in the areas of polyurethanes, polycarbonates, coating and adhesive raw materials, and specialty chemicals; and selected inorganic basic chemicals. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

118,888 Employees
Last Reported Date: 02/25/15
Founded in 1863

bayer ag-reg (BAYN) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €520.0K
Chief Strategy & Portfolio Officer and Member...
Total Annual Compensation: €2.0M
Labor Director and Member of Management Board
Total Annual Compensation: €1.6M
Member of Management Board, Chief Medical Off...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

bayer ag-reg (BAYN) Key Developments

Bayer To Sell Oral Contraceptive Pill Operation

South Korea's anti-trust regulator ordered the local subsidiary of Bayer AG (DB:BAYN) to sell its oral contraceptive pill operation that it acquired when its parent bought Merck & Co., citing conflicts with the country's fair trade rules. The Fair Trade Commission (FTC) said it ordered Bayer Korea Ltd. to dispose of its assets and rights related to all Mercilon tablet business in the country. "The decision was made because Bayer's dominance in a market that is already controlled by imported drugs could be detrimental to the interest of consumers," the FTC said, adding that the measure could preempt any moves by Bayer to hike up prices for its drugs.

Bayer Considering Multiple Strategic Alternatives For Home And Garden Consumer Products

Bayer AG (DB:BAYN) is considering multiple strategic alternatives for home and garden consumer products business. Germany's Bayer said it was considering strategic options for its home and garden consumer products business, maker of Baby Bio plant feed, as its crop protection arm focuses on professional customers. "A number of strategic alternatives are under consideration," a spokesman for the diversified drugs and pesticides maker said on March 20, 2015. People familiar with the matter told Reuters that Bayer was preparing to sell the business and was gauging the interest of prospective buyers, which could be private equity or industry players. The business generated €220 million euros in annual sales in 2014.

Bayer Reportedly Mulls Sale of Blood Glucose-Meter Business

Bayer AG (DB:BAYN) is reportedly seeking to sell blood glucose-meter business. Sources have said that Bayer is also looking into hiving off its blood glucose-meter business.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAYN:GR €139.19 EUR -0.57

BAYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $301.61 USD +0.98
Bristol-Myers Squibb Co $65.06 USD +0.355
Gilead Sciences Inc $101.30 USD +1.44
Merck & Co Inc $57.62 USD -0.64
Sanofi €91.38 EUR -0.76
View Industry Companies
 

Industry Analysis

BAYN

Industry Average

Valuation BAYN Industry Range
Price/Earnings 30.7x
Price/Sales 2.5x
Price/Book 5.2x
Price/Cash Flow 30.7x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAYER AG-REG, please visit www.bayer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.